trending Market Intelligence /marketintelligence/en/news-insights/trending/MJzKNxwhbEDYtuA-JuhXWQ2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Akeso Biopharma files for Hong Kong IPO

Blog

COVID-19 Impact & Recovery: Investment Banking

Blog

COVID-19 Impact & Recovery: Governments

Blog

COVID-19 Impact & Recovery: Academia

Blog

COVID-19 Impact & Recovery: Commercial Banks


Akeso Biopharma files for Hong Kong IPO

Akeso Biopharma Inc. filed to list its shares on the Hong Kong Stock Exchange.

The Guangdong, China-based privately held life sciences tools and services company acts as a contract research organization for pharmaceutical companies that focus on developing antibody drugs and protein-based drugs.

Akeso Biopharma previously announced that it received about $150 million in funding from existing and new investors.

Moreover, it entered into a joint venture in June with privately held pharmaceutical Jiangsu Chia-tai Tianqing Pharmaceutical Co. Ltd. to develop and commercialize a PD-1 antibody called AK105.